Systematic Review of the Epidemiology of Chagas Disease in the Americas: a Call for Standardized Reporting of Chagas Disease Prevalence

Miranda‐Schaeubinger, Monica; Chakravarti, Indira; Lidani, Kárita Cláudia Freitas; Omidian, Zahra; Gilman, Robert H.

doi:10.1007/s40475-019-00177-y

Cited by 10 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also highlights the potential need for standardized guidelines for diagnosis and testing according to the predominant lineage. Previous work from our team has highlighted these needs as well [6].…”

Section: Discussionmentioning

confidence: 99%

“…There are many obstacles to screening for T. cruzi infection in both endemic and nonendemic countries. A significant barrier is regional heterogeneity in disease prevalence, which creates an unclear picture of disease risk within a country or region [6]. Genetic diversity of the parasite may also create challenges for accurate diagnosis [19].…”

Section: Barriers To CD Diagnosis and Goals Of Studymentioning

confidence: 99%

“…cruzi is considered endemic in Mexico, where the WHO estimates a prevalence of nearly 0.800% [5]. However, this average misrepresents the wide prevalence variation across the country; regional CD prevalence across Mexico ranges from 0.36% to 20% [6]. CD prevalence is generally higher in rural regions [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City

et al. 2022

Self Cite

View full text Add to dashboard Cite

Trypanosoma cruzi infection leads to Chagas disease (CD), a neglected tropical infection of significant public health importance in South and Central America and other, non-endemic, countries. Pregnant women and their children are of particular importance to screen as T. cruzi can be transmitted vertically. The objective of this study was to screen for T. cruzi infection among pregnant women from endemic areas seen at the Hospital General de Mexico for prenatal care, so that they and their children may be quickly connected to CD treatment. Pregnant women were recruited through the hospital prenatal clinic and screened for T. cruzi infection using a series of serological and molecular tests. Of 150 screened patients, mean age 26.8 (SD 6.4), 30 (20.0%) were positive by at least one diagnostic test. Of these, only nine (6%) were positive as determined by PCR. Diagnosis of chronic CD is difficult in endemic places like Mexico due to the limitations of current commercially available diagnostic tests. Further evaluation of diagnostic performance of various assays could improve current CD diagnostic algorithms and proper care management in these regions. Genetic variability in the parasite may also play a role in the differing assay performances seen in this study, and this may be a valuable avenue of further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Barriers To CD Diagnosis and Goals Of Studymentioning

confidence: 99%

See 1 more Smart Citation

Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The dendrimer was used to encapsulate hydroxymethylnitrofurazone as a bioactive agent. Fernandez et al, evaluated the use of a first-generation dendrimer as a candidate for delivery of the anti- T. cruzi compound, (2′-(benzo [1,2-c] 1,2,5-oxadiazole-5(6)-yl (N-1-oxide) methylidene]-1-methoxy me- thane hydrazide), finding that dendrimers could be suitable for transporting antichagasic drugs. The research of Garolla and Fernández is reported in the work of Juárez-Chavéz et al (24).…”

Section: Introductionmentioning

confidence: 99%

“…Each year, 41,200 new cases of infected persons are reported, approximately 12,000 deaths per year due to cardiac complications, and 586 000 young adults of productive age are disabled. Currently, millions of chronically infected people are at risk of developing cardiovascular and/or digestive pathologies, making Chagas disease one of the main causes of morbidity and premature death due to cardiac complications in Latin America (5) (6). In addition, migratory phenomena have caused the expansion of the disease to non-endemic countries such as the United States, Canada and several European countries, Japan and Australia (5).…”

Section: Introductionmentioning

confidence: 99%

Synthesis and characterization of poly(propylene imine) dendrimers, as nanocarriers of Benznidazole: an in vitro controlled release assay

Ordoñez

Andrade

2022

Preprint

View full text Add to dashboard Cite

Background: American trypanosomiasis, or Chagas disease, is the result of an infection caused by the Trypanosoma cruzi parasite. The disease is endemic in Latin America, where the main clinical manifestation and cause of death of Chagas patients is cardiomyopathy. The current approved treatment for this disease is based on the use of the nitroheterocyclic compound, Benznidazole. The drug is administered in high doses and for prolonged periods, which causes serious adverse effects, eventually leading to treatment discontinuation. In addition, it has only shown efficacy in the acute phase of the disease. Benznidazole has low solubility, low permeability, low bioavailability and high toxicity in the body. These physicochemical characteristics can be improved by using dendritic structures that serve as nanocarriers. Methods: In this research, poly(propylene imine) PPI dendrimers in generations 4.0 G and 5.0 G were synthesized and characterized. We performed the synthesis by divergent approach. We encapsulated Benznidazole using the equilibrium dialysis method, and we evaluated the loading efficiency and the concentration of the released drug by high-performance liquid chromatography (HPLC). Results: Preliminary results showed a drug loading efficiency on the dendrimer of 78% and an entrapment percentage of 99.6%. The release kinetics showed a controlled and sustained release over time compared to dendrimer-free Benznidazole. Conclusions: The PPI 5.0 G - Benznidazole dendrimer system could be considered as an alternative to be evaluated in vitro and in vivo, as an alternative to conventional treatment of Chagas disease. The next stage of the experimental work consists of standardizing an infection model of H9C2 cardiomyocytes with Colombian strains of Trypanosoma cruzi, in order to evaluate the effect of the encapsulated drug on nanocarriers.

show abstract

Insights of potential trypanocidal effect of the synthetic derivative (2E)-1-(4-aminophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one: in vitro assay, MEV analysis, quantum study, molecular docking, molecular dynamics, MPO analysis, and predictive ADMET

Marinho,

da Rocha,

Magalhães

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Systematic Review of the Epidemiology of Chagas Disease in the Americas: a Call for Standardized Reporting of Chagas Disease Prevalence

Cited by 10 publications

References 40 publications

Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City

Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City

Synthesis and characterization of poly(propylene imine) dendrimers, as nanocarriers of Benznidazole: an in vitro controlled release assay

Insights of potential trypanocidal effect of the synthetic derivative (2E)-1-(4-aminophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one: in vitro assay, MEV analysis, quantum study, molecular docking, molecular dynamics, MPO analysis, and predictive ADMET

Contact Info

Product

Resources

About